English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

ROS1 (c-ros oncogene 1, receptor tyrosine kinase) rearrangements occur in 1–4% of patients with non-small cell lung cancer (NSCLC). Tyrosine kinase inhibitor (TKI) is recommended in the first-line setting in patients with metastatic NSCLC with ROS1 and ALK (anaplastic lymphoma receptor tyrosine kinase) rearrangements. Crizotinib is an oral, first-generation ALK, ROS1 and MET receptor TKI, which become the first-line treatment in patients with ALK-positive metastatic NSCLC. In PROFILE 1001 trial, the population of ROS1-positive patients, who had administered Crizotinib, median objective survival was more than 4 years. Crizotinib is also safe for long-term administration; thus, possible side effects are short-term.

Metastazavusio nesmulkiųjų ląstelių plaučių vėžio su ROS1 geno translokacija gydymo galimybės tirozino kinazės inhibitoriais